

| Day 1, 27 <sup>th</sup> September 2016 |   |   |  |       |                            |
|--|---|---|--|-------|----------------------------|
| 07.30                                  | <b>Registration &amp; Coffee</b>  |   |  |       |                            |
| 08.10                                  | Welcome Speech by Beth Jacobs, Managing Partner, Excellentia Global Partners  |   |  |       |                            |
| 08.20                                  | <b>State of the Markets: Pharma and Biotech</b><br>Chaired by:<br>Stephanie Léouzon, Partner, Torrey Partners (Europe), LLC<br>-<br>Panellists:<br>09.05 Chandra Leo, Investment Advisor, HBM Partners AG<br>Isabella Schidrich, Senior Managing Director, NASDAQ<br>Ryan Richardson, Vice President, Healthcare Investment Banking, JP Morgan Healthcare   |   |  |       |                            |
| 09.10                                  | <b>"Advances in Oncology Drug Discovery"</b><br>-<br>09.30 William Pao, Global Head of the Oncology Discovery and Translational Area (DTA), Roche Pharmaceutical Research & Early Development (pRED), F. Hoffmann-La Roche Ltd.   |   |  |       |                            |
| 09.35                                  | <b>"Collaboration Between Big and Small Viewed from Both Sides"</b><br>Christopher Viehbacher, Managing Partner, Gurnet Point Capital   | <b>Presentation Track A</b><br>Moderated by: Tomas Kahn     |  |       |                            |
| 09.55                                  |   | 09.30   | DiaMedica Inc. – [TSX-V:DMA] [OTCQB:DMCAF] |       |                            |
| 10.00                                  | <b>Global VC Roundtable</b><br>Co-Chaired by:<br>Bibhash Mukhopadhyay, Principal, New Enterprise Associates<br>Markus Hosang, General Partner, BioMedPartners AG<br>Panellists:<br>Genghis Lloyd-Harris, Partner, Abingworth LLP<br>John Gustofson, Sr. Director, Ventures & Early Stage Collaborations, AbbVie, Inc.<br>Martien van Osch, Managing Partner, Forbion Capital Partners<br>Matthew Foy, Partner, SR One<br>Monique Schiersing, Investment Director, F. Hoffmann-La Roche AG Roche Venture Fund<br>Otello Stampacchia, Managing Director, Omega Funds<br>Tony Rosenberg, Managing Director, MPM Capital LP | <b>Presentation Track B</b><br>Moderated by: Wilder Fulford |  |       |                            |
|  |   | 09.45   | Onconova Therapeutics - [NASDAQ: ONTX]     | 09.50 | [Reserved - InnaVirVax]    |
|  |   | 10.00   | Double Bond Pharmaceutical AB - [DBPB: SS] | 10.00 | Mymetics - [OTCMKTS: MYMX] |
|  |   | 10.15   | MOLOGEN AG - [MGN: GR]                     | 10.10 | Evaxion Biotech            |
|  |   | 10.30   | 4D Pharma Plc. - [LON: DDDD]               | 10.20 | Biologics Resources LLC    |
|  |   | 10.45   | RXi Pharmaceuticals, Inc. - [NASDAQ: RXII] | 10.30 | Strekin AG                 |
|  |   | 10.40   | ILTOO Pharma                               | 10.40 | ILTOO Pharma               |
|  |   | 10.50   | Inflamalps SA                              |       |                            |

| 11.00 <b>Coffee</b> |  |                     |  |  |                                  |  |                              |
|---------------------|--|---------------------|--|--|----------------------------------|--|------------------------------|
| 11.15<br>-<br>12.05 | <b>Buy-Side Perspectives</b><br>Chaired by:<br>Bob Pooler, Sr. Healthcare Analyst, valuationLAB AG<br>Panellists:<br>Chris Maggos, Managing Director, Europe, LifeSci Advisors<br>Christian Lach, Senior Portfolio Manager, Bellevue Asset Management AG<br>Ivo Stajjen, Head, Public Equity, HBM Partners AG<br>Kai Brüning, Senior Portfolio Manager, apo Asset Management GmbH<br>Thomas Stockman, Director, Healthcare Investment Banking, Royal Bank of Canada  | 11.15<br>-<br>12.00 | <b>Platform Technologies &amp; Novel Therapeutics</b><br>Chaired by:<br>Jane Atkins, Senior Director, GI Business Development, Takeda Pharmaceuticals International GmbH<br>Jasper Bos, Vice President and Head of Healthcare, Merck Ventures<br>Panellists:<br>Armin Mäder, CEO, Memo Therapeutics AG<br>Omar Haffar, Founder, President and CEO, Eos Biosciences, Inc.<br>Stefan Luzi, Associate, Gilde Healthcare Partners<br>Tibor Papp, Senior Director, Business Development, Haematology / Oncology / Transplantation, Shire Pharmaceuticals  | <b>Presentation Track C</b><br>Moderated by: Oliver Haslam |                                  | <b>Presentation Track D</b><br>Moderated by: TBA |                              |
|                     |  |                     |  | 11.15  | Atlantic Healthcare Plc.         | 11.15  | Pharmasum Therapeutics AS    |
|                     |  |                     |  | 11.30  | GeNeuro SA - [GNRO: FP]          | 11.25  | Prexton Therapeutics         |
|                     |  |                     |  | 11.45  | [Available]                      | 11.35  | Selonterra                   |
|                     |  |                     |  | 12.00  | CorMedix, Inc. - [NYSEMKT: CRMD] | 11.45  | Acticor Biotech SAS          |
|                     |  |                     |  |  |                                  | 11.55  | eTheRNA immunotherapies NV   |
| 12.10               | <b>Collaborations with Academic Medical Centres</b><br>Chaired by:<br>Edwin Constable, Vice-Rector Research, University of Basel<br>Luc Otten, Business Development, The Alpine Institute for Drug Discovery<br>Panellists:<br>Carolyn Porter, Deputy Head of Technology Transfer, Oxford University Innovation Ltd.<br>Dani Bach, Investments Director, Imperial Innovations<br>Dior Baumjohann, Technology Manager, Ascenion GmbH<br>Ernst Hafen, President, Bio-Technopark Zurich<br>Maria Bobadilla, Roche Partnering Innovation, F. Hoffmann-La Roche Ltd.<br>TBC, Inserm Transfert | 12.00               | <b>Autoimmune &amp; Inflammatory Diseases</b><br>Co-Chaired by:<br>Kia Motesharei, Head, Immunology Licensing, EMD Serono<br>Peter Dudek, Principal, Wellington Partners<br>Panellists:<br>Eric de La Fortelle, Venture Partner, Seventure Partners<br>Jérémie Mariau, CEO, ILTOO Pharma<br>Jesús Martin-Garcia, CEO, GeNeuro SA<br>Lesley Bester, Business Development Director, F. Hoffmann-La Roche Ltd.<br>Simon Blake, Sr. Director Scientific Licensing Immunology, Johnson & Johnson<br>Thomas Hanke, EVP, Head of Immunology & Inflammation, Evotec International GmbH<br>Toby Wilson Waterworth, CEO, Atlantic Healthcare plc | 12.15  | Allecrea Therapeutics GmbH       | 12.05  | ImmunoMet Therapeutics, Inc. |
|                     |  |                     |  | 12.30  | MDxHealth - [MDXH:BB]            | 12.15  | Nouscom AG                   |
|                     |  |                     |  |  |                                  | 12.25  | Provecs Medical GmbH         |
|                     |  |                     |  | 12.45  | Novogen Limited - [ASX: NRT]     | 12.35  | IO Biotech ApS               |
|                     |  |                     |  |  |                                  | 12.45  | ATRIVA Therapeutics GmbH     |


Host Sponsor:



Reception Sponsor:



Silver Sponsors:



Bronze Sponsors:



Supporters:



| 13.00 <u>Networking Lunch</u> |   |       |   |   |                       |  |                                  |
|-------------------------------|---|-------|---|---|-----------------------|--|----------------------------------|
| 14.00                         | <b>Neuroscience I – Alzheimer’s Disease</b><br>Co-Chaired by:<br>Fabrizio Gasparini, Director, Novartis Institutes for BioMedical Research<br>Tim Luker, Senior Director, External Innovation, Corp BD, Eli Lilly and Company<br>Panellists:<br>Carol Routledge, Venture Partner, SV Life Sciences<br>Charles Stacey, President and CEO, Accera, Inc.<br>David Reynolds, CSO, Alzheimer’s Research UK<br>Malcolm Weir, Co-Founder and CEO, Heptares Therapeutics  | 14.00 | <b>Vaccines &amp; Infectious Diseases</b><br>Co-Chaired by:<br>Chris Britten, Managing Director, Torrey Partners<br>Florian Schödel, Owner, Philimmune, LLC<br>Panellists:<br>Agnete Fredriksen, CSO, Vaccibody AS<br>Frederic Legros, VP Business Development, Valneva SE<br>Joël Crouzet, CEO, InnaVirVax<br>Randy Milby, CEO, CorMedix, Inc.<br>Ronald Kempers, President and CEO, Mymetics SA<br>Nicholas Benedict, Co-founder & CEO, Allecra Therapeutics GmbH | <b>Presentation Track E</b><br>Moderated by: Chris Maggos |                       | <b>Presentation Track F</b><br>Moderated by: Luc Otten |                                  |
|                               |   |       |   | 14.00   | [Available]           | 14.00  | Edinburgh Molecular Imaging Ltd. |
|                               |   |       |   | 14.15   | Biophytis             | 14.10  | ProAxis Ltd.                     |
|                               |   |       |   | 14.30   | Pantarhei Oncology    | 14.20  | Novigenix SA                     |
|                               |   |       |   | 14.45   | Avexxin AS            | 14.30  | TM3 Therapeutics                 |
|                               |   |       |   | 15.00   | Eos Biosciences, Inc. | 14.40  | RDD Pharma                       |
|                               |   |       |   | 15.15   | PeptiMimesis          | 14.50  | Ex Scientia Ltd.                 |
| 14.35                         | <b>Neuroscience II – Parkinson’s Disease &amp; Pain</b><br>Co-Chaired by:<br>Fabrizio Gasparini, Director, Novartis Institutes for BioMedical Research<br>Klaus Mendla, Head of Global Business Development and Licensing CNS, Boehringer Ingelheim<br>Panellists:<br>Arthur Roach, Director of Research, Parkinson’s UK<br>Timothy Morris, CFO, Head of Business Development, AcelRx Pharmaceuticals, Inc.<br>Francois Conquet, CEO, Prexton Therapeutics<br>Jörg Neermann, Partner, LSP<br>Kathryn Gregory, Executive Director, Licensing & Business Development, Purdue Pharma<br>Raghuram Selvaraju, Chairman of the Board of Directors, Relief Therapeutics Holding AG<br>Ronald Notvest, Executive Vice President, Commercial Planning and Development, Tonix Pharmaceuticals Holding Corp. | 14.55 | <b>Biomarkers &amp; Precision Medicine</b><br>Co-chaired by:<br>Alain Huriez, Partner, Advent Life Sciences<br>Rainer Metzger, VP Global Business Development Pharma, QIAGEN GmbH<br>Panellists:<br>Ian Wilson, CEO, Edinburgh Molecular Imaging Ltd.<br>Jan Groen, CEO, MDxHealth<br>Kevin Cox, CEO, Imanova Ltd.<br>Nicolas Demierre, COO, Novigenix  |   |                       | <b>Triskel Biopharmaceuticals AG</b>                   |                                  |
|                               |   |       |   |   |                       | 15.00  | Inserm DR Grand-Est              |
|                               |   |       |   |   |                       | 15.10  | CellProthera SAS                 |
|                               |   |       |   |   |                       |  |                                  |
|                               |   |       |   |   |                       |  |                                  |

|       |   |       |   |  |   |  |                            |
|-------|---|-------|---|--|---|--|----------------------------|
| 15.30 | <b>Coffee Break</b>   |       |   |  |   |  |                            |
| 15.45 | <b><u>Brexit: Implications for European Bio Pharma Innovation and Investment</u></b><br>Co-Chaired by:<br>John Rountree, Managing Partner, Novasecta Ltd.<br>Mike Ward, Chief Content Officer, Datamonitor Healthcare & Scrip Intelligence, Informa<br>Panellists:<br>Genghis Lloyd-Harris, Partner, Abingworth LLP<br>Gil Bar-Nahum, Managing Director in the Global Healthcare Investment Banking Group, Jefferies International<br>John Wilkinson, Partner, Cooley LLP<br>Paul Hermant, Head of Corporate Life Sciences, Bird & Bird | 15.45 | <b><u>Early Stage Investment</u></b><br>Co-Chaired by:<br>Nooman Haque, Director of Life Sciences, Silicon Valley Bank<br>Steve Dickman, Chief Executive Officer, CBT Advisors<br>Panellists:<br>Alexandra Richardson, Head of Business Development, Clayton Biotechnologies, Inc.<br>Fabian Buller, Director, New Ventures, J&J Innovation<br>Reza Halse, Head, European Innovation Hub, MSD<br>Sofia Ioannidou, Investment Director, Life Sciences, Edmond de Rothschild Investment Partners<br>Ulf Grawunder, CEO & Founder, NBE-Therapeutics Ltd. | <b>Presentation Track G</b><br>Moderated by: Hans Herklots |   | <b>Presentation Track H</b><br>Moderated by: Robin Davison |                            |
|       |   |       |   | 15.45  | Sensorion SA - [EPA: ALSEN]                         | 15.45  | Medesis Pharma SA          |
|       |   |       |   | 16.00  | Accera, Inc.  | 15.55  | GREENBONE ORTHO SRL        |
|       |   |       |   | 16.15  | Heptares Therapeutics                               | 16.05  | Anagenesis Biotechnologies |
|       |   |       |   | 16.30  | Purdue Pharma L.P.                                  | 16.15  | Elthera AG                 |
|       |   |       |   | 16.45  | Tonix Pharmaceuticals Holding Corp. - [NASDAQ:TNXP] | 16.25  | 3Brain GmbH                |
|       |   |       |   | 17.00  | Relief Therapeutics Holding AG                      | 16.35  | [Available]                |
|       |   |       |   | 17.15  | Addex Therapeutics Ltd.                             | 16.45  | [Available]                |
| 17.15 | <b><u>Israel Biomed Panel Discussion</u></b><br>Chaired by:<br>Laurent Choppe, Managing Partner, Cukierman & Co. Life Sciences<br>Panellists:<br>Jason Laufer, CEO, RDD Pharma<br>Michal Silverberg, Senior Director External Innovations, Takeda Ventures<br>Tamar Raz, CEO, Hadasit Ltd.<br>Yigal Yanai, CEO, PlasmaMedic Ltd.  | 17.15 | <b><u>Israel Biomed Panel: Elevator Session</u></b><br>Chaired by:<br>Laurent Choppe, Managing Partner, Cukierman & Co. Life Sciences<br>Presenting companies:<br>Alon Yaar, CEO, Curewize<br>Barak Zigdon, CEO, Z.M.D. Medical Ltd.<br>Issac Tal, CEO, TPCera<br>Jeniffer Yarden, CEO, BioShai<br>Moshik Cohen-Kutner, Co-Founder & CEO, Omnix Medical Ltd.<br>Tahel Altman, CEO, Synvaccine Ltd.<br>Tal Youdim, CTO, N2B<br>Zvica Goltzman, CEO, Saturix Ltd.   | 16.55  | [Available]   |  |                            |
|       |   |       |   | [Available]  |   |  |                            |
|       |   |       |   | [Available]  |   |  |                            |
| 18.00 | <b>End of The Day 1</b>   |       |   |  |   |  |                            |
| 19.00 | <b>Networking Reception at the Grand Hotel "Les Trois Rois"</b>   |       |   |  |   |  |                            |
| 21.00 | <b>End of Reception</b>   |       |   |  |   |  |                            |

Day 2, 28<sup>th</sup> September 2016

|       |  |  |  |
|-------|--|--|--|
| 08.00 | <b>Registration &amp; Coffee</b>   |  |  |
| 08.30 | <p><b>Presentation &amp; Discussion on “M&amp;A Deal Tectonics in Pharma &amp; Biotech”</b><br/>           Featuring:<br/>           Alexander Nuyken, Head of Life Sciences Transaction Advisory EMEA, Ernst &amp; Young GmbH<br/>           Jens Holstein, CFO, Morphosys<br/>           Matthias Bunte, Managing Partner &amp; Advisory Leader Industries Switzerland, Ernst &amp; Young AG</p>   |  |  |
| 09.00 | <p><b>Partnering: “How to Shape Deal Terms to Execute on Strategic Goals”</b><br/>           Chaired by:<br/>           Fintan Walton, CEO and Founder, PharmaVentures<br/>           Sarah Holland, Head of Europe, External Science and Partnering, Sanofi SA<br/>           Panellists:<br/>           Florence Dal Degan, R&amp;D Innovation Sourcing Director, Novo Nordisk<br/>           Janette Dean, Executive Director, Business Development Transactions, Bristol-Myers Squibb<br/>           Lubor Gaal, Head of Licensing and External Innovation, Almirall S.A.<br/>           Nathalie ter Wengel, European Head Global Scouting External R&amp;D Innovation, Pfizer<br/>           Paola Casarosa, Corporate Vice President, Business Development &amp; Licensing, Boehringer Ingelheim GmbH<br/>           Paul Hermant, Head of Corporate Life Sciences, Bird &amp; Bird<br/>           Stewart Kay, Director, Business Development, GSK</p> | <b>Presentation Track X</b><br>Moderated by: Steve Dickman |  |
|       |  | 09.00  | [Available]  |
|       |  | 09.15  | [Available]  |
|       |  | 09.30  | <b>Provectus Biopharmaceuticals, Inc. - [NYSE MKT: PVCT]</b> |
|       |  | 09.45  | <b>Targovax ASA</b>  |
| 10.00 | <b>Coffee Break</b>  |  |  |


**Host Sponsor:**



**Reception Sponsor:**



**Silver Sponsors:**



**Bronze Sponsors:**



**Supporters:**



|       |   |   |   |  |                               |
|-------|---|---|---|--|-------------------------------|
| 10.15 | <b><u>Oncology I – Partnering &amp; Development Opportunities</u></b><br>Co-Chaired by:<br>Esteban Pombo-Villar, Independent Consultant<br>Katya Smirnyagina, Partner, Capricorn Venture Partners<br>Panellists:<br>Austin Smith, Medical Director, Theradex (Europe) Ltd.<br>Göran Forsberg, CEO, Cantargia AB<br>Guillaume Vignon, Head of Immuno-Oncology Licensing & Business Development, EMD Serono<br>Juergen Gamer, VP Business Development, Apogenix AG<br>Loic Vincent, Head of Oncology External Innovation, Sanofi<br>Mark Vaeck, CEO, Complix NV<br>Vladimir Cmiljanovic, CEO, PIQUR Therapeutics AG | <b>Presentation Track A</b><br>Moderated by: Wilder Fulford |   | <b>Presentation Track B</b><br>Moderated by: Jørgen Thorball |                               |
|       |   | 10.15   | Galena Biopharma, Inc. – [NASDAQ: GALE]       | 10.15  | Synpromics Ltd.               |
|       |   | 10.30   | Arsanis, Inc.                                 | 10.25  | F2G Ltd.                      |
|       |   | 10.45   | AcelRx Pharmaceuticals, Inc. - [NASDAQ: ACRX] | 10.35  | Clayton Biotechnologies, Inc. |
|       |   |   |   | 10.45  | Novithera                     |
| 10.55 | Anima Biotech Ltd.  |   |   |  |                               |
| 11.15 | <b><u>Oncology II – Advances in IO &amp; Cell Therapy</u></b><br>Chaired by:<br>Tim Herpin, Vice President, Head of Transactions (UK), Business Development, AstraZeneca<br>Panellists:<br>Anthony DeBoer, Director, Business Development, Synaffix BV<br>Daniel Barton, Director of Business Development, Biosceptre International Ltd.<br>Marina Udier, COO, Nouscom AG<br>Mark Schwartz, President and CEO, Galena Biopharma, Inc.<br>Ramesh Kumar, President and CEO, Onconova Therapeutics<br>Stéphane Degove, CEO, GamaMabs Pharma SA   | 11.00   | Celyad S.A. - [CYAD: BB]                      | 11.05  | Lytix Biopharma AS            |
|       |   | 11.15   | Cellestia Biotech AG                          | 11.15  | [Available]                   |
|       |   |   |   | 11.25  | [Available]                   |
|       |   | 11.30   | Aurealis Pharma AG                            | 11.35  | [Available]                   |
|       |   | <b>Presentation Track C</b><br>Moderated by: Hans Herklots  |   | <b>Presentation Track D</b><br>Moderated by: Robin Davison   |                               |
| 12.15 | <b><u>Advances in Cell &amp; Gene Therapies</u></b><br>Chaired by:<br>Rao Movva, Novartis Distinguished Scientist (retired) & Currently Independent Biotech Advisor<br>Panellists:<br>David Venables, CEO, Synpromics Ltd.<br>Eric Halioua, President & CEO, PDC*line Pharma<br>Georges Rawadi, VP Business and Development, Celyad S.A.<br>Kilian Guse, CEO, Genequine Biotherapeutics GmbH<br>ZhiZhong Yao, Analyst, Sofinnova Partners   | 12.00   | PIQUR Therapeutics AG                         | 12.00  | Apogenix AG                   |
|       |   | 12.15   | GamaMabs Pharma SA                            | 12.15  | ImCyse                        |
|       |   | 12.30   | Cantargia AB - [CANTA.ST]                     | 12.30  | Biosceptre International Ltd. |
|       |   | 12.45   | Synaffix BV                                   | 12.45  | [Available]                   |
| 13.00 | <b>Networking Lunch</b>   |   |   |  |                               |
| 14.00 | <b><u>Interactive Workshop: by Pharma Ventures Ltd.</u></b>   |   |   |  |                               |
| 15.30 | <b>Last Chance to Network</b>   |   |   |  |                               |
| 16.30 | <b>End of the Forum</b>   |   |   |  |                               |